Combining vedolizumab and upadacitinib for ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether two medications, vedolizumab (a biologic given by IV) and upadacitinib (a pill), work together to help people with moderate to severe ulcerative colitis. The goal is to see if this combination is safe and effective for controlling symptoms and healing the colon.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have had ulcerative colitis for at least 3 months, confirmed by a scope and biopsy
- Have moderate to severe disease activity (Mayo score of 4 or more)
- Be considered a candidate for vedolizumab or upadacitinib treatment by your doctor
- Be able to take upadacitinib pills and receive vedolizumab through an IV
- Not have had most or all of your colon removed due to UC
- Not have active hepatitis B or C, or other serious uncontrolled medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
This trial tests a new drug, OD-07656, followed by vedolizumab, in people with moderate to severe ulcerative colitis. It aims to see if this approach is safe and helps control symptoms when other treatments have not worked well.
This study tests whether a higher dose of upadacitinib (45 mg) can help people with ulcerative colitis whose symptoms come back while on the usual 30 mg maintenance dose. If you've lost response to your current treatment, this re-induction approach may help you get back into remission.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
This trial tests combining two medicines, vedolizumab and upadacitinib, to see if they work better together than vedolizumab alone for people with moderate to severe Crohn's disease that hasn't responded well to other treatments.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.